Bayer (BAYRY) announced that the FDA accepted its supplemental new drug application and granted Priority Review designation for Kerendia, which is being investigated for the treatment of adults with type 1 diabetes and chronic kidney disease.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer upgraded to Buy from Hold at DZ Bank
- Bayer Tests Digital Heart Monitoring With ACO-Monitor: What Investors Should Watch
- Bayer granted priority review for asundexian by FDA
- Bayer Advances KRAS G12D Colorectal Cancer Study With New BAY 3771249 Trial
- Bayer announces HYRNUO sNDA granted Priority Review status by FDA